Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Hosted on MSN
Daiichi Sankyo’s Promising Study on R-DXd for Resistant Ovarian Cancer: A Market Game-Changer?
Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or lung cancer and active brain metastases, ...
This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results